Oncology & Cancer

Tool targets cancer-causing fusions' weak spot

Scientists at St. Jude Children's Research Hospital comprehensively characterized oncogenic fusions in pediatric cancer, providing proof-of-principle for genetic engineering-based therapies.

Oncology & Cancer

VCP/p97 as a therapeutic target in KRAS-mutant pancreatic cancer

A new research paper, titled "VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer," was published in Genes & Cancer on March ...

page 2 from 4